Physician and Patient Attitudes Toward Screening for Kidney Complications in Type 2 Diabetes: Is There A Role for Patient Self-Advocacy?
Copyright (c) 2018 Frischknecht et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Urine protein screening rates among patients with type 2 diabetes are suboptimal despite evidence supporting its efficacy in preventing or slowing the progression of diabetic kidney disease (DKD). Testing of untimed urine specimens to quantify albumin (urine albumin-creatinine, or uACR)-the recommended screening test based on combination of simplicity, cost, and cardiovascular and renal prognostic value-is particularly underutilized, despite longitudinal efforts to improve awareness and screening among physicians.